Role of Androgen Receptors as a Prognostic and Predictive Biomarker in Triple-Negative Breast Cancer

Current Breast Cancer Reports

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, and there are currently no targeted agents approved for its treatment. It is increasingly being realized that this entity by itself is quite heterogenous and the use of biomarkers can help in better characterization of its prognosis and development of appropriate therapeutic strategies. Recently, androgen receptors (AR) and their signaling cascade have been increasingly evaluated in TNBC. Their exact role in the pathogenesis and progression of the disease is still obscured. Drugs like bicalutamide and enzalutamide have shown some activity in this subtype. This review will focus on the available evidence supporting the role of androgen receptors in the prognosis of TNBC and current status of therapies targeting these receptors
December 2015
24 Reads

Similar Publications